Pat Arensdorf is the founder of Exai Bio. Exai Bio has raised $68M in total funding. Latest round: Series A. Based in San Francisco, CA, USA.
Patrick Arensdorf is the Chief Executive Officer at Exai Bio, a next-generation liquid biopsy company. He leads the company in developing a non-invasive, RNA-based liquid biopsy platform for early cancer detection. The platform uses orphan non-coding RNA (oncRNA) and artificial intelligence to provide clinical insight into cancer biology from blood samples.
Full founder directory · Investor directory · Company funding database · Fundraising library